| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
MAO-A 5.57 (pIC50)
(±)-Amiflamine targets the monoamine oxidase A (MAO-A) enzyme. By inhibiting MAO-A, it prevents the breakdown of serotonin and other monoamines, leading to increased neurotransmitter levels in the synaptic cleft. This mechanism is central to its use in studying conditions like depression and anxiety, where serotonergic signaling is often dysregulated. |
|---|---|
| ln Vitro |
In vitro, (±)-Amiflamine acts as a potent MAO-A inhibitor, with a pIC50 of 5.57. Its activity is typically evaluated in enzymatic assays using tissue homogenates or recombinant MAO-A. The compound's potency is determined by its ability to inhibit the oxidation of a substrate, such as kynuramine. This makes it a useful tool for studying the structure-activity relationship of MAO-A inhibitors.
|
| ln Vivo |
In vivo, (±)-Amiflamine's effects are primarily related to its MAO-A inhibition, which would be expected to increase central serotonin levels. This could translate to antidepressant or anxiolytic effects in animal models. However, comprehensive in vivo data for this specific racemic mixture are not detailed in the provided search results. Its use in research helps to elucidate the physiological roles of MAO-A.
|
| Enzyme Assay |
Non-cell-based assays to evaluate (±)-Amiflamine involve incubating the compound with a source of MAO-A (e.g., rat brain mitochondrial fractions or recombinant enzyme) and a substrate. The enzymatic activity is measured by monitoring the production of a reaction product, often using spectrophotometric or fluorometric methods. The decrease in product formation in the presence of the inhibitor is used to calculate the IC50 and pIC50 values.
|
| Cell Assay |
For in vitro cellular assays, (±)-Amiflamine could be used to study its effects on neurotransmitter metabolism in cell lines that express MAO-A. Cells are treated with the compound, and the subsequent changes in the levels of monoamines and their metabolites (e.g., via HPLC) are measured. This allows for the assessment of the inhibitor's efficacy in a cellular context, providing information beyond simple enzyme kinetics.
|
| Animal Protocol |
In vivo animal studies with (±)-Amiflamine would typically involve administering the compound to rodents (e.g., via intraperitoneal or oral routes) and then assessing its effects on behavior or neurochemistry. For example, its antidepressant-like effects could be evaluated in the forced swim test, and its impact on serotonin levels in specific brain regions could be measured ex vivo.
|
| ADME/Pharmacokinetics |
(±)-Amiflamine has a molecular weight of 192.30 g/mol and a molecular formula of C12H20N2. It appears as a solid and is typically supplied with a high purity (e.g., 99.23%). Its IUPAC name is 4-(2-aminopropyl)-N,N,3-trimethylaniline. For research purposes, it should be stored according to the manufacturer's instructions, typically at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (±)-Amiflamine is not extensively detailed in the provided search results. As a research chemical, comprehensive toxicological data are not typically available. It is intended for research use only and not for human consumption. Standard safety precautions for handling potent enzyme inhibitors should be observed.
|
| References | |
| Additional Infomation |
(±)-Amiflamine (CAS#: 77502-96-6) is a research tool primarily used to study MAO-A inhibition. Its racemic nature allows for the investigation of stereospecific effects of MAO-A inhibitors, as individual enantiomers may have different potencies and selectivities. It serves as a valuable compound for exploring the role of MAO-A in neuropsychiatric conditions and for the development of new therapeutic agents targeting this enzyme.
|
| Molecular Formula |
C12H20N2
|
|---|---|
| Molecular Weight |
192.30
|
| Exact Mass |
192.163
|
| CAS # |
77502-96-6
|
| Appearance |
Colorless to light yellow ointment
|
| LogP |
2.651
|
| SMILES |
CCC(C1=C(C=C(C=C1)N(C)C)C)N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2002 mL | 26.0010 mL | 52.0021 mL | |
| 5 mM | 1.0400 mL | 5.2002 mL | 10.4004 mL | |
| 10 mM | 0.5200 mL | 2.6001 mL | 5.2002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
